ClearPoint Neuro, Inc. (CLPT) News

ClearPoint Neuro, Inc. (CLPT): $6.20

0.20 (-3.13%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Filter CLPT News Items

CLPT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CLPT News Highlights

  • For CLPT, its 30 day story count is now at 2.
  • Over the past 27 days, the trend for CLPT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest CLPT News From Around the Web

Below are the latest news stories about CLEARPOINT NEURO INC that investors may wish to consider to help them evaluate CLPT as an investment opportunity.

Those who invested in ClearPoint Neuro (NASDAQ:CLPT) five years ago are up 365%

Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are...

Yahoo | December 19, 2023

7 Solid Small-Caps for 2024 and Beyond

Small-cap stocks are positioned to beat the biggest companies in 2024 as risk tolerance climbs and shares remain undervalued

Jeremy Flint on InvestorPlace | December 5, 2023

Are Investors Undervaluing ClearPoint Neuro, Inc. (NASDAQ:CLPT) By 41%?

Key Insights The projected fair value for ClearPoint Neuro is US$10.08 based on 2 Stage Free Cash Flow to Equity...

Yahoo | November 22, 2023

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2023 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2023 Earnings Call Transcript November 9, 2023 ClearPoint Neuro, Inc. beats earnings expectations. Reported EPS is $-0.0002, expectations were $-0.25. Operator: Thank you for standing by, and welcome to the ClearPoint Neuro, Inc. Q3 2023 Earnings Conference Call. Comments made on this call may include statements that are forward-looking within […]

Yahoo | November 10, 2023

ClearPoint Neuro Reports Third Quarter 2023 Results

Biologics & Drug Delivery Growing 55%; Q3 Operational Cash Burn of $1.8MSOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023. Third Quarter Highlights Reported quarterly revenue of $5.8 million, a 12% year-over-year increase;Increased biologics and drug delivery revenue

Yahoo | November 9, 2023

ClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023

SOLANA BEACH, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 third quarter on Thursday, November 9, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company’s 2023 third quarter on Thursday, November 9, 2023, at 4:30 p.m. Eastern time

Yahoo | October 26, 2023

When Should You Buy ClearPoint Neuro, Inc. (NASDAQ:CLPT)?

ClearPoint Neuro, Inc. ( NASDAQ:CLPT ), might not be a large cap stock, but it led the NASDAQCM gainers with a...

Yahoo | October 26, 2023

ClearPoint Neuro Reports Second Quarter 2023 Results

Biologics & Drug Delivery growing +40%; Company Reaffirms 2023 Revenue ForecastSOLANA BEACH, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2023. Second Quarter Highlights Reported record quarterly revenue of $6.0 million, a 14% year-over-year increase;Increased biologics and drug deliv

Yahoo | August 8, 2023

ClearPoint Neuro to Announce Second Quarter 2023 Results August 8, 2023

SOLANA BEACH, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 second quarter on Tuesday, August 8, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company’s 2023 second quarter on Tuesday, August 8, 2023, at 4:30 p.m. Eastern time (1:3

Yahoo | July 25, 2023

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio. “We are extremely excited to partner with UCB, a global biopharmaceutical leader, with a focus on inno

Yahoo | May 24, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!